The natural life tables of diamonthback moth (DBM), Plutella xylostella under pesticides treatment were constructed,and the construction method of item "pesticide" was particularly discussed.The life tables ...The natural life tables of diamonthback moth (DBM), Plutella xylostella under pesticides treatment were constructed,and the construction method of item "pesticide" was particularly discussed.The life tables indicated that the indices of population trend (I) under the treatment with 80% Dichlorvos EC 1000x and the contrast were 0.7796 and 1.4804, respectively,showing that Dichlorvos had some control on DBM. But,Dichlorvos had some effects on natural enemies of DBM. The decrease of parasitism rate at pupa stage was most obvious,which indicated that Dichlorvos had some effects of killing and wounding on the natural enemies of DBM.展开更多
To quantify drug-drug-interactions (DDIs) encountered in patients prescribed hepatitis C virus (HCV) treatment, the interventions made, and the time spent in this process.METHODSAs standard of care, a clinical pharmac...To quantify drug-drug-interactions (DDIs) encountered in patients prescribed hepatitis C virus (HCV) treatment, the interventions made, and the time spent in this process.METHODSAs standard of care, a clinical pharmacist screened for DDIs in patients prescribed direct acting antiviral (DAA) HCV treatment between November 2013 and July 2015 at the University of Colorado Hepatology Clinic. HCV regimens prescribed included ledipasvir/sofosbuvir (LDV/SOF), paritaprevir/ritonavir/ombitasvir/dasabuvir (OBV/PTV/r + DSV), simeprevir/sofosbuvir (SIM/SOF), and sofosbuvir/ribavirin (SOF/RBV). This retrospective analysis reviewed the work completed by the clinical pharmacist in order to measure the aims identified for the study. The number and type of DDIs identified were summarized with descriptive statistics.RESULTSSix hundred and sixty four patients (83.4% Caucasian, 57% male, average 56.7 years old) were identified; 369 for LDV/SOF, 48 for OBV/PTV/r + DSV, 114 for SIM/SOF, and 133 for SOF/RBV. Fifty-one point five per cent of patients were cirrhotic. Overall, 5217 medications were reviewed (7.86 medications per patient) and 781 interactions identified (1.18 interactions per patient). The number of interactions were fewest for SOF/RBV (0.17 interactions per patient) and highest for OBV/PTV/r + DSV (2.48 interactions per patient). LDV/SOF and SIM/SOF had similar number of interactions (1.28 and 1.48 interactions per patient, respectively). Gastric acid modifiers and vitamin/herbal supplements commonly caused interactions with LDV/SOF. Hypertensive agents, analgesics, and psychiatric medications frequently caused interactions with OBV/PTV/r + DSV and SIM/SOF. To manage these interactions, the pharmacists most often recommended discontinuing the medication (28.9%), increasing monitoring for toxicities (24.1%), or separating administration times (18.2%). The pharmacist chart review for each patient usually took approximately 30 min, with additional time for more complex patients.CONCLUSIONDDIs are common with HCV medications and management can require medication adjustments and increased monitoring. An interdisciplinary team including a clinical pharmacist can optimize patient care.展开更多
The objective of this research was to isolate a dichlorvos (2,2-dichlorovinyl dimethyl phosphate)-degrading strain of Ochrobactrum sp., and determine its effectiveness in remediation of a dichlorvos-contaminated soil....The objective of this research was to isolate a dichlorvos (2,2-dichlorovinyl dimethyl phosphate)-degrading strain of Ochrobactrum sp., and determine its effectiveness in remediation of a dichlorvos-contaminated soil. A dichlorvos-degrading bacterium (strain DDV-1) was successfully isolated and identified as an Ochrobactrumsp. based on its 16S rDNA sequence analysis. Strain DDV-1 was able to utilize dichlorvos as a sole carbon source, and the optimal pH and temperature for its cell growth and degradation were 7.0 and 30 ℃, respectively. Also, the growth and degradation of strain DDV-1 showed the same response to dissolved oxygen. In addition, the soil degradation test indicated that in soil spiked with 100 mg L-1 or 500 mg L-1 dichlorvos and inoculated with 0.5% or 1.0% (v/v) strain DDV-1, complete degradation of dichlorvos could be achieved in 24 h. The present study showed that strain DDV-1 was a fast dichlorvos-degrading bacterium in soil. However, further research will be needed to clarify the degradation pathway and the properties of the key enzymes involved in its biodegradation.展开更多
Objective： To explore the feasibility of transfecting cytidine deaminase （CD） gene into mouse bone marrow cells in order to observe the drug resistance of high dose Ara-C and improve the tolerance of myelosuppressi...Objective： To explore the feasibility of transfecting cytidine deaminase （CD） gene into mouse bone marrow cells in order to observe the drug resistance of high dose Ara-C and improve the tolerance of myelosuppression following combination chemotherapy. Methods： Human cytidine deaminase gene was transfected into mice bone marrow cells by retroviral vector. Resistant colony-forming unit granulocyte-macrophage （CFU-GM） assay was performed after the transfected mice bone marrow cells treated by the Ara-C. DNA was extracted from mice bone marrow cells. The drug resistant gene in mice bone marrow cells after transfection was detected by PCR. Results： Bone marrow cells of the donor mice cultured with the retroviral producer cells showed the drug resistant colonies and resistance to Ara-C, so did accept mice transplanted with the CD gene （CFU-GM of donor mice was 52%, χ^2 = 124.62, P 〈 0.01; accept mice was 54%, χ^2 = 126.26, P 〈 0.01, both compared with the contrast group）. The animal survival rate was significantly higher in gene transfected group than that of the control （χ^2= 7.42, P 〈 0.01）. CD gene of transfected bone marrow cells was confirmed by PCR. Conclusion： CD gene can be transfected into bone marrow cells of mice efficiently and increase the drug resistance to Ara-C.展开更多
P-glycoprotein(P-gp)is an important transmembrane ATP-binding cassette(ABC)drug efflux transporter expressed in various human tissues such as the intestines,liver,kidneys,and bloodbrain barrier.It limits the intracell...P-glycoprotein(P-gp)is an important transmembrane ATP-binding cassette(ABC)drug efflux transporter expressed in various human tissues such as the intestines,liver,kidneys,and bloodbrain barrier.It limits the intracellular concentration of xenobiotics by pumping them out of the cells,affecting drug pharmacokinetics and therapeutic effects.With its broad substrate specificity,it has the potential to remove a wide range of drugs from Chinese materia medica(CMM),including conventional medicines and active compounds.Increasing evidence has confirmed the superior therapeutic effectiveness of CMM in treating a wide range of diseases worldwide,as well as in conjunction with western drugs.As a result,herbal medicine-drug compounds have prompted widespread concern,with the majority of these interactions involving transporters such as P-gp.This review systematically summarizes the inhibition or induction of P-gp expression/function by active CMM compounds and the underlying regulatory mechanisms.It will aid in improving understanding of the synergistic or inhibiting effects associated with transporter P-gp as well as rational safety concerns for using CMM,particularly in combination with drugs.展开更多
Over the last decade, the standard of care for the treat- ment of chronic hepatitis C has been the combination of pegylated-interferon-alfa （PEG-IFN） and ribavirin （RBV） which results in sustained virological resp...Over the last decade, the standard of care for the treat- ment of chronic hepatitis C has been the combination of pegylated-interferon-alfa （PEG-IFN） and ribavirin （RBV） which results in sustained virological response （SVR） rates of 75%-85% in patients with genotypes 2 or 3 but only of 40%-50% in patients with genotype 1. Cur- rently, there are rapid and continuous developments of numerous new agents against hepatitis C virus （HCV）, which are the focus of this review. Boceprevir and tela- previr, two first-generation NS3/4A HCV protease inhibi- tors, have been recently licensed in several countries around the world to be used in combination with PEG- IFN and RBV for the treatment of genotype 1 patients. Boceprevir or telaprevir based triple regimens, com- pared with the PEG-IFN/RBV combination, improve the SVR rates by 25%-31% in treatment-naTve genotype 1 patients, by 40%-64% in prior relapsers, by 33%-45% in prior partial responders and by 24%-28% in prior null responders. At the same time, the application of response-guided treatment algorithms according to the on-treatment virological response results in shortening of the total therapy duration to only 24 wk in 45%-55% of treatment-na＇ive patients. There are, however, several challenges with the use of the new triple combinations in genotype 1 patients, such as the need for immediate results of HCV RNA testing using sensitive quantitative assays, new and more frequent adverse events （anemia and dysgeusia for boceprevir; pruritus, rash and anemia for telaprevir）, new drug interactions and increasing dif- ficulties in compliance. Moreover, the SVR rates are still poor in very difficult to treat subgroups of genotype 1 patients, such as null responders with cirrhosis, while there is no benefit for patients who cannot tolerate PEG- IFN/RBV or who are infected with non-1 HCV genotype. Many newer anti-HCV agents of different classes and numerous combinations are currently under evaluation with encouraging results. Preliminary data suggest that the treatment of chronic HCV patients with well toler- ated combinations of oral agents without PEG-IFN is feasible and may lead to a universal HCV cure over the next 5-10 years.展开更多
Esterases participate in the metabolism of^10%of the clinical drugs that contain ester or amide bonds,but the esterases mediated drug/herb-drug interactions(DDIs or HDIs)have not been reviewed in depth.Carboxylesteras...Esterases participate in the metabolism of^10%of the clinical drugs that contain ester or amide bonds,but the esterases mediated drug/herb-drug interactions(DDIs or HDIs)have not been reviewed in depth.Carboxylesterases(CEs),the most abundant esterases expressed in the metabolic organ of mammals,play a pivotal role in hydrolysis of a variety of endogenous and xenobiotic esters.In the human body,two predominant carboxylesterases including hCE1 and hCE2 have been identified and extensively studied over the past decade.These two enzymes have been found with hydrolytic activity towards a variety of endogenous esters and ester-containing drugs.Recent studies have demonstrated that strong inhibition on hCEs may slow down the hydrolysis of CEs substrates,which may affect their pharmacokinetic properties and thus trigger potential DDIs or HDIs.Over the past decade,many herbal extracts and herbal constitutes have been found with strong inhibitory effects against CEs,and their potential risks on herb-drug interactions(HDIs)have also attracted much attention.This review focused on recent progress in hCEs mediated herb-drug interactions.The roles of hCEs in drug metabolism,the inhibitory capacities and inhibition mechanism of a variety of herbal extract and herbal constitutes against hCEs have been well summarized.Furthermore,the challenges and future perspectives in this field are highlighted by the authors.All information and knowledge presented in this review will be very helpful for the pharmacologists to deeper understand the metabolic interactions between herbal constituents and hCEs,as well as for clinical clinicians to reasonable use herbal medicines for alleviating hCEs-associated drug toxicity or avoiding the occurrence of clinically relevant hCEs-mediated HDIs.展开更多
Capparis spinosa L. is a traditionally used plant in Algerian folk medicine to treat asthma, rheumatism and other free radicals related disorders such inflammatory. The present study was designated to study the antiox...Capparis spinosa L. is a traditionally used plant in Algerian folk medicine to treat asthma, rheumatism and other free radicals related disorders such inflammatory. The present study was designated to study the antioxidant activity of aerial and root parts of Capparis spinosa L.. Total polyphenol content was determined, after extraction with solvents in five subfractions; methanol （CE）, Hexan （HE） chloroform （CHE）, ethyl acetate （EAE） and aqueous extracts （AE）, employing the ＂Prussian blue assay＂. The results showed that EAE containing the highest concentration of phenolic compounds and Flavonoids followed by those of CHE of aerial and root parts, repectively. The antioxidant protective effects of extracts were determined by measuring the erythrocyte membrane resistance to free radical-induced. The results demonstrated that all the extracts exhibited a protective effect against t-BHP induced oxidative damages in human erythrocytes, the most potents wer CEs and CHEs with 86.55%, 85.81%, 74.59%, and 68.70%, for aerial and root parts, respectively, which were more effective than used standards： Quercetin （65.46%） and rutin （59.62%）. In order to more clarify the previous antioxidants activity of the extracts through other mechanisms, the iron chelating ability assays were realized. The results showed that the iron chelating ability of Aerial and root extracts were very considerable; the CE showed an excellent chelating with ICs0 of 0.197 ± 0.031 μM/quercetin equivalent, higher than that used standard EDTA, with approximately 0.34 folds. These results show that Capparis spinosa L. extracts have strong anti-oxidant effects and may have some clinical benefits.展开更多
文摘The natural life tables of diamonthback moth (DBM), Plutella xylostella under pesticides treatment were constructed,and the construction method of item "pesticide" was particularly discussed.The life tables indicated that the indices of population trend (I) under the treatment with 80% Dichlorvos EC 1000x and the contrast were 0.7796 and 1.4804, respectively,showing that Dichlorvos had some control on DBM. But,Dichlorvos had some effects on natural enemies of DBM. The decrease of parasitism rate at pupa stage was most obvious,which indicated that Dichlorvos had some effects of killing and wounding on the natural enemies of DBM.
文摘To quantify drug-drug-interactions (DDIs) encountered in patients prescribed hepatitis C virus (HCV) treatment, the interventions made, and the time spent in this process.METHODSAs standard of care, a clinical pharmacist screened for DDIs in patients prescribed direct acting antiviral (DAA) HCV treatment between November 2013 and July 2015 at the University of Colorado Hepatology Clinic. HCV regimens prescribed included ledipasvir/sofosbuvir (LDV/SOF), paritaprevir/ritonavir/ombitasvir/dasabuvir (OBV/PTV/r + DSV), simeprevir/sofosbuvir (SIM/SOF), and sofosbuvir/ribavirin (SOF/RBV). This retrospective analysis reviewed the work completed by the clinical pharmacist in order to measure the aims identified for the study. The number and type of DDIs identified were summarized with descriptive statistics.RESULTSSix hundred and sixty four patients (83.4% Caucasian, 57% male, average 56.7 years old) were identified; 369 for LDV/SOF, 48 for OBV/PTV/r + DSV, 114 for SIM/SOF, and 133 for SOF/RBV. Fifty-one point five per cent of patients were cirrhotic. Overall, 5217 medications were reviewed (7.86 medications per patient) and 781 interactions identified (1.18 interactions per patient). The number of interactions were fewest for SOF/RBV (0.17 interactions per patient) and highest for OBV/PTV/r + DSV (2.48 interactions per patient). LDV/SOF and SIM/SOF had similar number of interactions (1.28 and 1.48 interactions per patient, respectively). Gastric acid modifiers and vitamin/herbal supplements commonly caused interactions with LDV/SOF. Hypertensive agents, analgesics, and psychiatric medications frequently caused interactions with OBV/PTV/r + DSV and SIM/SOF. To manage these interactions, the pharmacists most often recommended discontinuing the medication (28.9%), increasing monitoring for toxicities (24.1%), or separating administration times (18.2%). The pharmacist chart review for each patient usually took approximately 30 min, with additional time for more complex patients.CONCLUSIONDDIs are common with HCV medications and management can require medication adjustments and increased monitoring. An interdisciplinary team including a clinical pharmacist can optimize patient care.
基金Project supported by the National High Technology Research and Development Program of China (863 Program)(Nos.2001AA214121, 2002AA246081 and 2003AA241150)the National Key Technologies Research and Development Program of China during the 9th Five-Year Plan Period (No. 2002BA516A01)the National Natural Science Foundation of China (No. 30400013).
文摘The objective of this research was to isolate a dichlorvos (2,2-dichlorovinyl dimethyl phosphate)-degrading strain of Ochrobactrum sp., and determine its effectiveness in remediation of a dichlorvos-contaminated soil. A dichlorvos-degrading bacterium (strain DDV-1) was successfully isolated and identified as an Ochrobactrumsp. based on its 16S rDNA sequence analysis. Strain DDV-1 was able to utilize dichlorvos as a sole carbon source, and the optimal pH and temperature for its cell growth and degradation were 7.0 and 30 ℃, respectively. Also, the growth and degradation of strain DDV-1 showed the same response to dissolved oxygen. In addition, the soil degradation test indicated that in soil spiked with 100 mg L-1 or 500 mg L-1 dichlorvos and inoculated with 0.5% or 1.0% (v/v) strain DDV-1, complete degradation of dichlorvos could be achieved in 24 h. The present study showed that strain DDV-1 was a fast dichlorvos-degrading bacterium in soil. However, further research will be needed to clarify the degradation pathway and the properties of the key enzymes involved in its biodegradation.
基金Supported by a grant from the NationaI-Naturl Science Foundation of China （No. 30471678）.
文摘Objective： To explore the feasibility of transfecting cytidine deaminase （CD） gene into mouse bone marrow cells in order to observe the drug resistance of high dose Ara-C and improve the tolerance of myelosuppression following combination chemotherapy. Methods： Human cytidine deaminase gene was transfected into mice bone marrow cells by retroviral vector. Resistant colony-forming unit granulocyte-macrophage （CFU-GM） assay was performed after the transfected mice bone marrow cells treated by the Ara-C. DNA was extracted from mice bone marrow cells. The drug resistant gene in mice bone marrow cells after transfection was detected by PCR. Results： Bone marrow cells of the donor mice cultured with the retroviral producer cells showed the drug resistant colonies and resistance to Ara-C, so did accept mice transplanted with the CD gene （CFU-GM of donor mice was 52%, χ^2 = 124.62, P 〈 0.01; accept mice was 54%, χ^2 = 126.26, P 〈 0.01, both compared with the contrast group）. The animal survival rate was significantly higher in gene transfected group than that of the control （χ^2= 7.42, P 〈 0.01）. CD gene of transfected bone marrow cells was confirmed by PCR. Conclusion： CD gene can be transfected into bone marrow cells of mice efficiently and increase the drug resistance to Ara-C.
基金the Macao Science and Technology Development Fund(No.0067/2019/A2 and No.0075/2019/AMJ)from the Macao Special Administrative Region。
文摘P-glycoprotein(P-gp)is an important transmembrane ATP-binding cassette(ABC)drug efflux transporter expressed in various human tissues such as the intestines,liver,kidneys,and bloodbrain barrier.It limits the intracellular concentration of xenobiotics by pumping them out of the cells,affecting drug pharmacokinetics and therapeutic effects.With its broad substrate specificity,it has the potential to remove a wide range of drugs from Chinese materia medica(CMM),including conventional medicines and active compounds.Increasing evidence has confirmed the superior therapeutic effectiveness of CMM in treating a wide range of diseases worldwide,as well as in conjunction with western drugs.As a result,herbal medicine-drug compounds have prompted widespread concern,with the majority of these interactions involving transporters such as P-gp.This review systematically summarizes the inhibition or induction of P-gp expression/function by active CMM compounds and the underlying regulatory mechanisms.It will aid in improving understanding of the synergistic or inhibiting effects associated with transporter P-gp as well as rational safety concerns for using CMM,particularly in combination with drugs.
文摘Over the last decade, the standard of care for the treat- ment of chronic hepatitis C has been the combination of pegylated-interferon-alfa （PEG-IFN） and ribavirin （RBV） which results in sustained virological response （SVR） rates of 75%-85% in patients with genotypes 2 or 3 but only of 40%-50% in patients with genotype 1. Cur- rently, there are rapid and continuous developments of numerous new agents against hepatitis C virus （HCV）, which are the focus of this review. Boceprevir and tela- previr, two first-generation NS3/4A HCV protease inhibi- tors, have been recently licensed in several countries around the world to be used in combination with PEG- IFN and RBV for the treatment of genotype 1 patients. Boceprevir or telaprevir based triple regimens, com- pared with the PEG-IFN/RBV combination, improve the SVR rates by 25%-31% in treatment-naTve genotype 1 patients, by 40%-64% in prior relapsers, by 33%-45% in prior partial responders and by 24%-28% in prior null responders. At the same time, the application of response-guided treatment algorithms according to the on-treatment virological response results in shortening of the total therapy duration to only 24 wk in 45%-55% of treatment-na＇ive patients. There are, however, several challenges with the use of the new triple combinations in genotype 1 patients, such as the need for immediate results of HCV RNA testing using sensitive quantitative assays, new and more frequent adverse events （anemia and dysgeusia for boceprevir; pruritus, rash and anemia for telaprevir）, new drug interactions and increasing dif- ficulties in compliance. Moreover, the SVR rates are still poor in very difficult to treat subgroups of genotype 1 patients, such as null responders with cirrhosis, while there is no benefit for patients who cannot tolerate PEG- IFN/RBV or who are infected with non-1 HCV genotype. Many newer anti-HCV agents of different classes and numerous combinations are currently under evaluation with encouraging results. Preliminary data suggest that the treatment of chronic HCV patients with well toler- ated combinations of oral agents without PEG-IFN is feasible and may lead to a universal HCV cure over the next 5-10 years.
基金the National Key Research and Development Program of China(2017YFC1700200,2017YFC1702000)the National Scientific and Technological Major Projects of China(2017ZX09101004)+3 种基金the National Natural Science Foundation of China(81703604,81773687 and 81573501)Program of Shanghai Academic/Technology Research Leader(18XD1403600)Shuguang Program(No.18SG40)Shanghai Education Development Foundation and Shanghai Municipal Education Commission,Project funded by China Postdoctoral Science Foundation(2017M621520,and 2018T110406).
文摘Esterases participate in the metabolism of^10%of the clinical drugs that contain ester or amide bonds,but the esterases mediated drug/herb-drug interactions(DDIs or HDIs)have not been reviewed in depth.Carboxylesterases(CEs),the most abundant esterases expressed in the metabolic organ of mammals,play a pivotal role in hydrolysis of a variety of endogenous and xenobiotic esters.In the human body,two predominant carboxylesterases including hCE1 and hCE2 have been identified and extensively studied over the past decade.These two enzymes have been found with hydrolytic activity towards a variety of endogenous esters and ester-containing drugs.Recent studies have demonstrated that strong inhibition on hCEs may slow down the hydrolysis of CEs substrates,which may affect their pharmacokinetic properties and thus trigger potential DDIs or HDIs.Over the past decade,many herbal extracts and herbal constitutes have been found with strong inhibitory effects against CEs,and their potential risks on herb-drug interactions(HDIs)have also attracted much attention.This review focused on recent progress in hCEs mediated herb-drug interactions.The roles of hCEs in drug metabolism,the inhibitory capacities and inhibition mechanism of a variety of herbal extract and herbal constitutes against hCEs have been well summarized.Furthermore,the challenges and future perspectives in this field are highlighted by the authors.All information and knowledge presented in this review will be very helpful for the pharmacologists to deeper understand the metabolic interactions between herbal constituents and hCEs,as well as for clinical clinicians to reasonable use herbal medicines for alleviating hCEs-associated drug toxicity or avoiding the occurrence of clinically relevant hCEs-mediated HDIs.
文摘Capparis spinosa L. is a traditionally used plant in Algerian folk medicine to treat asthma, rheumatism and other free radicals related disorders such inflammatory. The present study was designated to study the antioxidant activity of aerial and root parts of Capparis spinosa L.. Total polyphenol content was determined, after extraction with solvents in five subfractions; methanol （CE）, Hexan （HE） chloroform （CHE）, ethyl acetate （EAE） and aqueous extracts （AE）, employing the ＂Prussian blue assay＂. The results showed that EAE containing the highest concentration of phenolic compounds and Flavonoids followed by those of CHE of aerial and root parts, repectively. The antioxidant protective effects of extracts were determined by measuring the erythrocyte membrane resistance to free radical-induced. The results demonstrated that all the extracts exhibited a protective effect against t-BHP induced oxidative damages in human erythrocytes, the most potents wer CEs and CHEs with 86.55%, 85.81%, 74.59%, and 68.70%, for aerial and root parts, respectively, which were more effective than used standards： Quercetin （65.46%） and rutin （59.62%）. In order to more clarify the previous antioxidants activity of the extracts through other mechanisms, the iron chelating ability assays were realized. The results showed that the iron chelating ability of Aerial and root extracts were very considerable; the CE showed an excellent chelating with ICs0 of 0.197 ± 0.031 μM/quercetin equivalent, higher than that used standard EDTA, with approximately 0.34 folds. These results show that Capparis spinosa L. extracts have strong anti-oxidant effects and may have some clinical benefits.
